TCGX
About TCGX
TCG Crossover is a science-driven investment firm focused on advancing disruptive medicines. The firm operates in the life sciences investment space, funding and guiding early- to late-stage pharmaceutical and biotech ventures with a mission to accelerate breakthrough therapies. Based on the information available, it emphasizes scientific rigor and portfolio development in the biopharma sector, and positions itself as a dedicated investor in breakthrough medicines. The organization is associated with its online presence and professional network, including a LinkedIn profile.
Recent News
ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript
InMed‑Mentari All‑Stock Merger Sends Shares Up 160% and Triggers $290 Million Private Placement
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Jefferies Initiates Vor Biopharma Stock with Buy Rating on Autoimmune Pivot
Corxel Draws $287M Round to Drive Global Development of Oral GLP-1